IPO market abuzz with biotech offerings
The buzz is biotech — at least as far as initial public offerings are concerned in the fourth quarter.
IPO market abuzz with biotech offerings
The buzz is biotech — at least as far as initial public offerings are concerned in the fourth quarter.